Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome

Mayo Clinic Proceedings

Volumn 77, Issue 2, 2002, Pages 197-200

  Bouwhuis, Saskia A ^a   Markovic, Svetomir N ^a   McEvoy, Marian T ^a   Pittelkow, Mark R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PSORALEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AEROSOL; ARTICLE; CASE REPORT; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; EXTRACORPOREAL CIRCULATION; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MALE; NONHODGKIN LYMPHOMA; PHOTOCHEMISTRY; PUVA; SEZARY CELL; SEZARY SYNDROME; T CELL LYMPHOMA; T LYMPHOCYTE SUBPOPULATION; ULTRAVIOLET A RADIATION;

EID: 0036158592     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/77.2.197     Document Type: Article

References (25)

1. Cutaneous T-cell lymphoma
2. Mycosis fungoides and the Sézary syndrome
3. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome
4. Emerging new therapies for cutaneous T-cell lymphoma
5. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: Preliminary results
6. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy
7. Extracorporeal photopheresis in Sézary syndrome: No significant effect in the survival of 44 patients with a peripheral blood T-cell clone
8. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: A 10-year experience at a single institution
9. Effectiveness of photopheresis in Sézary syndrome
10. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy
11. PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes
12. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor
13. Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma
14. The dentritic cell: Its potent role in the respiratory immune response
15. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia
16. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients
17. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer
18. Biological concepts of prolonged neoadjuvant treatment plus GM-CSF in locally advanced tumors
19. Aerosol granulocyte macrophage-colony stimulating factor: A low toxicity, lung-specific biological therapy in patients with lung metastases
20. Granulocyte-macrophage colony-stimulating factor overrides the immunosuppressive function of corticosteroids on rat pulmonary dendritic cells
21. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: A prospective controlled trial
22. The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma
23. Transgenic expression of granulocyte-macrophage colony-stimulating factor induces the differentiation and activation of a novel dendritic cell population in the lung
24. Dendritic cell precursors are enriched in the vascular compartment of the lung
25. Expression of apoptosis markers on peripheral blood lymphocytes from patients with cutaneous T-cell lymphoma during extracorporeal photochemotherapy